Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abou Family ResidenceXTAE:ABOU 21 ROE % is 0.00% as of . 20. GuruFocus rates XTAE:ABOU with a GF Score™ of 21/100. The stock has 1 warning sign investors should review. Among 799 Medical Devices & Instruments companies, Abou Family Residence ranks worse than 125156.32% on this metric.
The historical rank and industry rank for Abou Family Residence's ROE % or its related term are showing as below:
XTAE:ABOU's ROE % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.54 * Ranked among companies with meaningful ROE % only.
Abou Family Residence (XTAE:ABOU) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is one times the annual (. 20) net income data. The Revenue data used here is one times the annual (. 20) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abou Family Residence ROE % Chart
Abou Family Residence Annual Data
Trend
ROE %
Abou Family Residence Semi-Annual Data
ROE %
XTAE:ABOU vs ABT, SYK, MDT: ROE % Comparison
For the Medical Devices subindustry, Abou Family Residence's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abou Family Residence ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Abou Family Residence's ROE % distribution charts can be found below:
* The bar in red indicates where Abou Family Residence's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is one times the annual (. 20) net income data.
ROE % is displayed in the 30-year financial page.
* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.
Abou Family Residence (XTAE:ABOU) has a ROE % of 0.00% as of . 20. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Abou Family Residence and its competitors. According to the industry distribution chart, Abou Family Residence ranks #999999 out of 799 companies in the Medical Devices & Instruments industry.
Is Abou Family Residence's ROE % too high?
Abou Family Residence's current ROE % is 0.00%. Based on the distribution chart, Abou Family Residence ranks #999999 out of 799 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Abou Family Residence has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Abou Family Residence's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Abou Family Residence ranks #999999 out of 799 companies for ROE %. This places Abou Family Residence in the lower half of its industry. The industry median ROE % is 2.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.54, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Abou Family Residence and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abou Family Residence's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abou Family Residence stock overvalued right now?
Abou Family Residence (XTAE:ABOU) has a current ROE % of 0.00%. The current ROE % is 0.00%. Abou Family Residence's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Abou Family Residence (XTAE:ABOU), the current ROE % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Abou Family Residence Ltd formerly Envizion Medical Ltd is a medical device company. It is focused on improving patient outcomes across the continuum of care, encompassing the development of advanced, personalized navigation technology for feeding tubes, responding to the challenges of the ever changing healthcare environment, while continuously focusing on the customer.
21GF Score
Get the complete analysis for XTAE:ABOU
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:ABOU has been successfully added to your 
